NSIX -- Neuromedical Systems, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NSIX -- Neuromedical Systems, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: TLWatson59 who wrote (72)	1/21/1998 7:26:00 PM
From: Daniel Rimar	Read Replies (1) of 137

Please read: The new press release was not from NSIX, but came out of Chicago. I don't think the study is very a very fair representation of the cost effectiveness of Papnet. I work in the field and use Papnet. The cases for this study had already been screened by a cytechnologist and determined to be negative. If the cases were screened by a competent cytotechnologist you would not expect to find many new abnormal cases out of that case pool. From the press release: "Laurie Mango, chief medical officer for Neuromedical Systems, said the study's results can be called into question because they came from a high-level lab not prone to mistakes and involved a well-screened group of women whose smears had already been tested twice." If these cases had not been pre-screened, Papnet would have found many more abnormal cases per negative case, and the cost effective- ness would have been much much better. Right now all cases for sent for Papnet testing must first be screened by a cytotechnologist, and be determined that they are negative. If Papnet should ever receive FDA approval for primary screening this would not be the case. This little gem today cost the stock $1 per share or 25%. I think we may be getting into buying opportunity territory. I hope this study will be looked at for what it truely says which is that even acompetant cytotechnologist may occasionally miss an abnormal case, and Papnet was able to find these abnormal cases preventing false negative results from being released for a patient. Dan

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next